Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 23, 2020 (6 years ago)

R.E.C.K. (Ropivacaine, Epinephrine, Clonidine, Ketorolac)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Presence of Particulate Matter: Fresenius Kabi recalling vials of Ketorolac

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

R.E.C.K. (Ropivacaine, Epinephrine, Clonidine, Ketorolac) in Sodium Chloride solution 50 mL in 60 mL Syringe, Compounded by QuVa 519 Bloombury, NJ 08804, NDC 70092143350

Affected NDC 70092-1433-50

Compare with the code on your package — it is the most precise check available.

Drug: Epinephrine

Recalling firm
QuVa Pharma, Inc.
Origin
TX, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1335-2020 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Epinephrine recalls

See all
Class I · High risk

Epinephrine Injection

Presence of Particulate Matter and Lack of Assurance of Sterility. Particulate matter identified as nylon, cellulosic, acrylic, polyethylene and glass and broken and leaking vials.

Ongoing Sterility / contamination American Regent, Inc. NDC 0517-3030-01 D-0865-2026
Class II · Moderate risk

Maximum

Stability Data Does Not Support Expiry Date.

Ongoing Stability / shelf life HTO Nevada Inc. dba Kirkman D-0387-2026

Other recalls by QuVa Pharma, Inc.

All 2020 recalls